#GEP-NETs
$CATX: VMT-α-NET 39% response rate in GEP-NETs; $236.9M cash at June 30; end-of-Phase 2 FDA meeting guided for Q1 2027.
Hub: https://www.merlintrader.com/perspective-therapeutics-catx-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
November 10, 2026 at 7:50 PM
Resolving gastroenteropancreatic neuroendocrine tumor (GEP-NET) heterogeneity: doi.org/10.1172/JCI2...
@vanallenlab.bsky.social & team coupled sequencing with spatial transcriptomics in 38 GEP-NETs, finding a continuum of neuronal-like & secretory neuroendocrine cell states with prognostic value.
November 6, 2026 at 1:05 PM
GEP NETs are the most common NETs. Symptoms often mimic common gastric conditions.
📢Join us on November 10th, #NETCancerDay, to raise awareness of NETs among HCPs – this will help them SUSPECT and DETECT the disease.
✅Join us in your language: incalliance.org/ncd-2026/cam...
#LetsTalkAboutNETs
October 26, 2026 at 7:42 AM
A Simplified Dosimetry Approach for Treating GEP-NETs: What New Research Reveals
www.diagnosticimaging.com/shorts/simpl...
#radiology #RadRes #NuclearMedicine
October 23, 2026 at 3:36 PM
Did you miss this week's key updates in GEP-NETs, NMIBC, pancreatic cancer, and HCC? Test your knowledge with OncLive's weekly news quiz #blcsm #HCC #pancsm #oncology

www.onclive.com/view/onclive...
OncLive Weekly News Quiz (10/16/2026): Did You Miss Crucial Bladder, Neuroendocrine, Pancreatic, and Liver Cancer Updates? | OncLive
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
www.onclive.com
October 16, 2026 at 2:57 PM
Clinical Trials - Targeted Alpha-Emitter PRRT RYZ101/RYZ401 ronnyallan.net/2022/09/14/c...
Clinical Trials - Targeted Alpha-Emitter PRRT RYZ101/RYZ401 - Ronny Allan - Living with Neuroendocrine Cancer
Discover the benefits of alpha-emitter PRRT in treating GEP-NETs. Learn about the positive results from the ACTION-1 trial.
ronnyallan.net
October 13, 2026 at 12:31 PM
Could Future Research Lead to Personalized Treatment with 177Lu-Edotreotide for GEP-NETs?
www.diagnosticimaging.com/shorts/futur...
#radiology #RadRes #NuclearMedicine
October 12, 2026 at 9:20 PM
📈 RYZ101 led to a statistically significant and clinically meaningful PFS improvement vs SOC in SSTR+ GEP-NETs after progression on Lu-177, meeting the primary end point of the phase 3 ACTION-1 trial. @sunnybrookhsc.bsky.social #oncology

Read more ➡️: www.onclive.com/view/ryz101-...
RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs | OncLive
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
www.onclive.com
October 12, 2026 at 3:14 PM
#$BMY RYZ101 met its primary endpoint with a significant PFS benefit in advanced GEP-NETs after Lu177 therapy. First Phase 3 results for an alpha-emitting radiopharmaceutical. notreload.xyz/xy/bms-ryz10...
BMS RYZ101 Hits Primary Endpoint in Late-Stage NET Study
RYZ101 delivered a statistically significant PFS improvement in the Phase 3 ACTION-1 trial for SSTR+ GEP-NETs after Lu177 therapy. Safety consistent with prior data.
notreload.xyz
October 12, 2026 at 11:59 AM
New option for gastroenteropancreatic neuroendocrine tumors: FDA grants approval to Bexlutry.

Specific eligibility criteria apply; see the linked briefing.

How many patients could be eligible for Bexlutry under its approved indication?
Bexlutry: a new option for gastroenteropancreatic neuroendocrine tumors
FDA approval for Bexlutry, 14 Sep 2026. Eligible adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Source: FDA approval notice and the FDA-approved label.
enclai.net
October 9, 2026 at 1:00 AM
Curium's lutetium Lu 177 dotatate (BEXLUTRY) gains FDA approval for somatostatin receptor-positive GEP-NETs in adults via 505(b)(2) pathway. A second-generation entry into an established market.
Curium wins FDA approval for BEXLUTRY lutetium RLT in GEP-NETs
Curium's BEXLUTRY, a 505(b)(2) lutetium Lu 177 dotatate equivalent, has received FDA approval for somatostatin receptor-positive GEP-NETs in adults.
biotech.disruptsmedia.com
September 28, 2026 at 2:00 PM
📰 The @fda.gov has approved and granted competitive generic therapy designation to lanreotide injection, a generic formulation referencing lanreotide, for the treatment of patients with GEP-NETs. #oncology

Full story ➡️: www.onclive.com/view/fda-app...
FDA Approves Generic Lanreotide Injection for GEP-NETs | OncLive
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
www.onclive.com
September 22, 2026 at 10:01 PM
US FDA Approves Radioequivalent Lu 177 Dotatate Product BRAVNETSA for GEP-NETs ronnyallan.net/2024/01/12/f...
September 22, 2026 at 4:37 PM
📰 #Finance

"BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today that the U.S. Food and Drug Administration (FDA) has…"
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
financialpost.com
September 14, 2026 at 10:27 PM
Now on demand ▶️

Gain practical insights for NET management.

Sessions available:

🔹 Early NET Treatment Decisions: Recognizing When to Initiate and Escalate Therapy
🔹 Advanced GEP-NET Management: Personalizing Systemic and Targeted Therapy

Watch now: bit.ly/4epl13N

#NETs #GEPNETs #Oncology
June 24, 2026 at 8:00 PM
A new review by Virginia Corbett, Garima Gupta, and Aman Chauhan synthesises recent clinical trials, cohort studies, and expert consensus to clarify the role of peptide receptor radionuclide therapy in neuroendocrine tumours management.

Read the review #OpenAccess: doi.org/10.1530/ERC-...
April 14, 2026 at 10:55 AM
Advanced Accelerator Applications, USA, Inc. v. Lantheus Medical Imaging, Inc.
Advanced Accelerator Applications, USA, Inc. v. Lantheus Medical Imaging, Inc.
Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (“GEP-NETs”). The...
www.jdsupra.com
July 20, 2026 at 6:55 PM
Inside April Issue: have a look at Nature Cancer issue featuring GEP-NETs, CART, prostate cancer, renal cell carcinoma, bacteria in cancer therapy, gallbladder lesions, lung cancer, ESMO TAT reports, and much more

👉 nature.com/natcancer/
April 28, 2025 at 3:25 PM
November is #GastricCancerAwarenessMonth.
👉60% of NETs are gastro-intestinal or pancreatic NETs (GEP NET).
👉Approx. 50% of GEP NET patients are misdiagnosed with IBS or gastritis. (SCAN2019)
✅Get to know NETs with #NETInfo in 12 languages: incalliance.org/net-info-pac... #LetsTalkAboutNETs
November 26, 2025 at 8:32 AM
April is #IBSAwarenessMonth. IBS can very often be one of the misdiagnoses for GEP NET.
👉To better equip clinicians to suspect an uncommon condition, we need to give them a snapshot of NETs.
📌Mind NETs with #NETInfo in 11 languages: incalliance.org/net-info-pac...
#LetsTalkAboutNETs
April 23, 2025 at 2:11 PM